Please login to the form below
bimagrumab
This page shows the latest bimagrumab news and features for those working in and with pharma, biotech and healthcare.
Pfizer abandons antibody for Duchenne
Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this
Latest news
-
Novartis orphan drug wins 'breakthrough' status from FDA
A monoclonal antibody, bimagrumab was developed by the Novartis Institutes for Biomedical Research (NIBR) in collaboration with Morphosys, whose HuCAL library was used to identify the antibody. ... With no effective therapies currently available for sIBM,
Novartis orphan drug wins 'breakthrough' status from FDA
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Future of MHRA uncertain amid Brexit-fuelled shake up
- UK announces COVID boosters for a “bumpy winter” ahead
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
